Literature DB >> 10529694

Factor Xa and prothrombin: mechanism of action of FEIBA.

P L Turecek1, K Varadi, H Gritsch, W Auer, L Pichler, G Eder, H P Schwarz.   

Abstract

A complex consisting of activated factor X (FX) (enzyme) and prothrombin (substrate), both highly purified from human plasma and virus inactivated, was formulated, characterised biochemically as well as in animal studies, and given the name Partial Prothrombinase (PPT). In vitro, PPT shortened the clotting time of a high-titre human factor VIII (FVIII) inhibitor plasma in a manner similar to that of the activated prothrombin complex concentrate FEIBA and triggered coagulation in plasma samples in which factor V (FV) is present. In vivo, the ability of PPT to activate coagulation in both chimpanzees and baboons was equivalent to that of FEIBA. PPT also triggered coagulation in a von Willebrand factor(vWF)-deficient dog and controlled bleeding in rabbits with antibody-induced haemophilia A. Thus, studying the mechanism of action of PPT also explains the therapeutic principle of FEIBA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529694     DOI: 10.1159/000056722

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

Review 1.  Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.

Authors:  Nabil K Thalji; Rodney M Camire
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

Review 2.  Current options and new developments in the treatment of haemophilia.

Authors:  Trisha Wong; Michael Recht
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

3.  Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia.

Authors:  Galila Zaher; Soheir Adam
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-04-02       Impact factor: 2.576

Review 4.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007

Review 5.  Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine.

Authors:  François Depasse; Nikolaus B Binder; Julia Mueller; Thomas Wissel; Stephan Schwers; Matthias Germer; Björn Hermes; Peter L Turecek
Journal:  J Thromb Haemost       Date:  2021-09-26       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.